362 results on '"Rondoni, Michela"'
Search Results
2. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
3. Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients
4. Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis
5. Novel insights and therapeutic approaches in secondary AML.
6. Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia.
7. Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival
8. MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis
9. P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
10. Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience
11. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
12. New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders
13. Abstract 6163: Fusion landscape in acute leukemias: A submerged world of not routinely characterized transcripts
14. Issue <scp>Highlights—July</scp> 2022
15. Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in 'Real-Life': The SEIFEM Experience
16. Additional file 1 of SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
17. SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
18. Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)
19. Poster: MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis
20. Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
21. CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program
22. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
23. MPN-180: A Novel Mechanism of Action of Midostaurin in Systemic Mastocytosis: Beyond KIT Inhibition
24. Poster: MPN-180: A Novel Mechanism of Action of Midostaurin in Systemic Mastocytosis: Beyond KIT Inhibition
25. Late Hematologic Recovery after CPX-351 Induction Chemotherapy in AML: Predictive Disease and Patient's Factors and Their Impact on Survival
26. Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study
27. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias
28. Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia
29. Exploring the ATR-CHK1 Pathway in the Response of Doxorubicin-induced DNA Damages in Acute Lymphoblastic Leukemia Cells
30. Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
31. Advanced mast cell disease: an Italian Hematological Multicenter experience
32. Mast cell leukemia: a report of ten cases
33. PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment
34. Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series
35. SETD2 loss of function as a new marker of advanced disease in systemic mastocytosis: biological and clinical implications
36. Rearrangements of ATP5L‐KMT2A in acute lymphoblastic leukaemia
37. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia
38. MDS-227: Digital PCR for Sensitive Detection and Accurate Quantification of KIT D816V Allele Burden in Patients with Suspected Systemic Mastocytosis
39. MPN-204: Midostaurin Synergizes with Nilotinib and Dasatinib Restoring SETD2 Expression and Activity in Advanced Systemic Mastocytosis
40. CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
41. Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination
42. A der(1)t(1;21)(p36.3;q22) in a Patient with Acute Myelogenous Leukemia M2
43. Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients
44. In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors
45. Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion
46. Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome–Positive Leukemia
47. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
48. Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia
49. Real‐world experience with decitabine as a first‐line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy
50. MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.